HAEMONETICS CORP/MASS (HAE) Fundamental Analysis & Valuation

NYSE:HAE • US4050241003

59.41 USD
-1.21 (-2%)
Last: Mar 12, 2026, 03:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This HAE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to HAE. HAE was compared to 184 industry peers in the Health Care Equipment & Supplies industry. HAE scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on HAE.


Dividend Valuation Growth Profitability Health

8

1. HAE Profitability Analysis

1.1 Basic Checks

  • HAE had positive earnings in the past year.
  • In the past year HAE had a positive cash flow from operations.
  • HAE had positive earnings in each of the past 5 years.
  • HAE had a positive operating cash flow in each of the past 5 years.
HAE Yearly Net Income VS EBIT VS OCF VS FCFHAE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

1.2 Ratios

  • HAE has a better Return On Assets (7.04%) than 86.96% of its industry peers.
  • HAE's Return On Equity of 19.25% is amongst the best of the industry. HAE outperforms 92.93% of its industry peers.
  • With an excellent Return On Invested Capital value of 10.45%, HAE belongs to the best of the industry, outperforming 90.22% of the companies in the same industry.
  • HAE had an Average Return On Invested Capital over the past 3 years of 8.96%. This is in line with the industry average of 9.15%.
  • The last Return On Invested Capital (10.45%) for HAE is above the 3 year average (8.96%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.04%
ROE 19.25%
ROIC 10.45%
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
HAE Yearly ROA, ROE, ROICHAE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15 20

1.3 Margins

  • With an excellent Profit Margin value of 13.31%, HAE belongs to the best of the industry, outperforming 89.67% of the companies in the same industry.
  • In the last couple of years the Profit Margin of HAE has grown nicely.
  • HAE has a Operating Margin of 19.76%. This is amongst the best in the industry. HAE outperforms 91.30% of its industry peers.
  • In the last couple of years the Operating Margin of HAE has remained more or less at the same level.
  • With a Gross Margin value of 59.32%, HAE perfoms like the industry average, outperforming 59.78% of the companies in the same industry.
  • In the last couple of years the Gross Margin of HAE has grown nicely.
Industry RankSector Rank
OM 19.76%
PM (TTM) 13.31%
GM 59.32%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
HAE Yearly Profit, Operating, Gross MarginsHAE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. HAE Health Analysis

2.1 Basic Checks

  • HAE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • HAE has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for HAE has been reduced compared to 5 years ago.
  • Compared to 1 year ago, HAE has a worse debt to assets ratio.
HAE Yearly Shares OutstandingHAE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
HAE Yearly Total Debt VS Total AssetsHAE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 2.35 indicates that HAE is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.35, HAE is doing good in the industry, outperforming 64.67% of the companies in the same industry.
  • HAE has a debt to FCF ratio of 4.77. This is a neutral value as HAE would need 4.77 years to pay back of all of its debts.
  • HAE has a better Debt to FCF ratio (4.77) than 78.26% of its industry peers.
  • A Debt/Equity ratio of 1.01 is on the high side and indicates that HAE has dependencies on debt financing.
  • The Debt to Equity ratio of HAE (1.01) is worse than 75.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF 4.77
Altman-Z 2.35
ROIC/WACC1.19
WACC8.8%
HAE Yearly LT Debt VS Equity VS FCFHAE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • HAE has a Current Ratio of 1.75. This is a normal value and indicates that HAE is financially healthy and should not expect problems in meeting its short term obligations.
  • HAE's Current ratio of 1.75 is on the low side compared to the rest of the industry. HAE is outperformed by 67.93% of its industry peers.
  • A Quick Ratio of 1.15 indicates that HAE should not have too much problems paying its short term obligations.
  • The Quick ratio of HAE (1.15) is worse than 71.74% of its industry peers.
Industry RankSector Rank
Current Ratio 1.75
Quick Ratio 1.15
HAE Yearly Current Assets VS Current LiabilitesHAE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. HAE Growth Analysis

3.1 Past

  • HAE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.31%, which is quite good.
  • HAE shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.66% yearly.
  • HAE shows a decrease in Revenue. In the last year, the revenue decreased by -4.02%.
  • HAE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.60% yearly.
EPS 1Y (TTM)16.31%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%10.08%
Revenue 1Y (TTM)-4.02%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-2.75%

3.2 Future

  • HAE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.00% yearly.
  • Based on estimates for the next years, HAE will show a small growth in Revenue. The Revenue will grow by 3.06% on average per year.
EPS Next Y9.31%
EPS Next 2Y8.45%
EPS Next 3Y9%
EPS Next 5YN/A
Revenue Next Year-2.55%
Revenue Next 2Y1.37%
Revenue Next 3Y3.06%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HAE Yearly Revenue VS EstimatesHAE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
HAE Yearly EPS VS EstimatesHAE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

8

4. HAE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.08, HAE is valued correctly.
  • HAE's Price/Earnings ratio is rather cheap when compared to the industry. HAE is cheaper than 90.22% of the companies in the same industry.
  • HAE is valuated cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 11.05, which indicates a very decent valuation of HAE.
  • 92.39% of the companies in the same industry are more expensive than HAE, based on the Price/Forward Earnings ratio.
  • HAE is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.27, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.08
Fwd PE 11.05
HAE Price Earnings VS Forward Price EarningsHAE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 92.39% of the companies in the same industry are more expensive than HAE, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, HAE is valued cheaply inside the industry as 97.83% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 10.74
EV/EBITDA 9.86
HAE Per share dataHAE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • HAE's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • HAE has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.3
PEG (5Y)1.81
EPS Next 2Y8.45%
EPS Next 3Y9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HAE Dividend Analysis

5.1 Amount

  • HAE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HAE Fundamentals: All Metrics, Ratios and Statistics

HAEMONETICS CORP/MASS

NYSE:HAE (3/12/2026, 3:03:51 PM)

59.41

-1.21 (-2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners112.31%
Inst Owner Change-0.5%
Ins Owners1.18%
Ins Owner Change0.09%
Market Cap2.76B
Revenue(TTM)1.32B
Net Income(TTM)175.44M
Analysts78.67
Price Target89.76 (51.09%)
Short Float %5.53%
Short Ratio3.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.51%
Min EPS beat(2)3.75%
Max EPS beat(2)13.26%
EPS beat(4)4
Avg EPS beat(4)6.21%
Min EPS beat(4)0.62%
Max EPS beat(4)13.26%
EPS beat(8)7
Avg EPS beat(8)3.66%
EPS beat(12)11
Avg EPS beat(12)8.29%
EPS beat(16)15
Avg EPS beat(16)9.12%
Revenue beat(2)2
Avg Revenue beat(2)2.64%
Min Revenue beat(2)1.21%
Max Revenue beat(2)4.07%
Revenue beat(4)3
Avg Revenue beat(4)2.3%
Min Revenue beat(4)-0.63%
Max Revenue beat(4)4.55%
Revenue beat(8)4
Avg Revenue beat(8)1.17%
Revenue beat(12)8
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)2.47%
PT rev (1m)-4.35%
PT rev (3m)4.09%
EPS NQ rev (1m)-1.89%
EPS NQ rev (3m)-1.89%
EPS NY rev (1m)0.66%
EPS NY rev (3m)0.66%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)0.53%
Valuation
Industry RankSector Rank
PE 12.08
Fwd PE 11.05
P/S 2.09
P/FCF 10.74
P/OCF 8.15
P/B 3.03
P/tB N/A
EV/EBITDA 9.86
EPS(TTM)4.92
EY8.28%
EPS(NY)5.37
Fwd EY9.05%
FCF(TTM)5.53
FCFY9.31%
OCF(TTM)7.29
OCFY12.27%
SpS28.37
BVpS19.61
TBVpS-2.48
PEG (NY)1.3
PEG (5Y)1.81
Graham Number46.6
Profitability
Industry RankSector Rank
ROA 7.04%
ROE 19.25%
ROCE 13.35%
ROIC 10.45%
ROICexc 12.84%
ROICexgc 36.33%
OM 19.76%
PM (TTM) 13.31%
GM 59.32%
FCFM 19.5%
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
ROICexc(3y)10.46%
ROICexc(5y)8.47%
ROICexgc(3y)26.78%
ROICexgc(5y)22.33%
ROCE(3y)11.45%
ROCE(5y)9.23%
ROICexgc growth 3Y22.36%
ROICexgc growth 5Y7.33%
ROICexc growth 3Y21.7%
ROICexc growth 5Y-5.09%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
F-Score7
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF 4.77
Debt/EBITDA 2.47
Cap/Depr 72.66%
Cap/Sales 6.21%
Interest Coverage 250
Cash Conversion 90.81%
Profit Quality 146.5%
Current Ratio 1.75
Quick Ratio 1.15
Altman-Z 2.35
F-Score7
WACC8.8%
ROIC/WACC1.19
Cap/Depr(3y)79.52%
Cap/Depr(5y)76.24%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.58%
Profit Quality(3y)103.91%
Profit Quality(5y)115.34%
High Growth Momentum
Growth
EPS 1Y (TTM)16.31%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%10.08%
EPS Next Y9.31%
EPS Next 2Y8.45%
EPS Next 3Y9%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.02%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-2.75%
Revenue Next Year-2.55%
Revenue Next 2Y1.37%
Revenue Next 3Y3.06%
Revenue Next 5YN/A
EBIT growth 1Y19.07%
EBIT growth 3Y34.59%
EBIT growth 5Y7.12%
EBIT Next Year31.99%
EBIT Next 3Y14.22%
EBIT Next 5YN/A
FCF growth 1Y99.46%
FCF growth 3Y16.98%
FCF growth 5Y2.09%
OCF growth 1Y71.68%
OCF growth 3Y1.79%
OCF growth 5Y2.81%

HAEMONETICS CORP/MASS / HAE FAQ

What is the ChartMill fundamental rating of HAEMONETICS CORP/MASS (HAE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to HAE.


Can you provide the valuation status for HAEMONETICS CORP/MASS?

ChartMill assigns a valuation rating of 8 / 10 to HAEMONETICS CORP/MASS (HAE). This can be considered as Undervalued.


What is the profitability of HAE stock?

HAEMONETICS CORP/MASS (HAE) has a profitability rating of 8 / 10.


Can you provide the expected EPS growth for HAE stock?

The Earnings per Share (EPS) of HAEMONETICS CORP/MASS (HAE) is expected to grow by 9.31% in the next year.